Status:
UNKNOWN
Inflammatory Markers Dynamics in Response to Extra-corporeal Membrane Oxygenator Decannulation
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Extracorporeal membrane oxygenation (ECMO) aim at providing cardiac, respiratory support, or both. The use of ECMO could be associated with systemic inflammatory response syndrome (SIRS) at the time o...
Eligibility Criteria
Inclusion
- ALL ECMO patients candidates for decannulation
Exclusion
- patients who have identified sepsis prior to decannulation, febrile patients, patient who receive steroids and patient who die within 48 hours after ECMO decannulation.
Key Trial Info
Start Date :
February 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04678518
Start Date
February 28 2023
End Date
December 31 2023
Last Update
May 19 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad medical corporation
Doha, DA, Qatar, 3050
2
Hamad medical corporation
Doha, DA, Qatar, 3050